A polypeptide fragment and its preparation method and application
By developing a polypeptide fragment derived from nucleolar phosphate protein, which can bind to cadmium ions, it solves the problems of poor efficacy and major side effects of existing cadmium poisoning treatment methods, and significantly improves the survival rate of cadmium-exposed cells and animal models and Resistance.
Patent Information
- Application Number
- CN202411045064.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-01
AI Technical Summary
Existing treatments for cadmium poisoning such as antioxidant methods and chelation methods have problems with poor efficacy and major side effects, and it is difficult to effectively eliminate cadmium accumulation in the body, resulting in cell and organ damage.
A polypeptide fragment derived from the amino acid sequence of nucleolar phosphate protein (NPM1) can be developed, capable of binding to cadmium ions, expressed and purified by specific preparative methods, to improve animal and cell resistance to cadmium.
Experimental results show that the peptide fragment significantly improves the survival rate of cadmium-exposed cells and animal models, reduces the symptoms of liver damage and weight loss caused by cadmium, and has potential pharmacological activities to treat and prevent cadmium poisoning.
Smart Images

Figure CN118561960B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to a polypeptide fragment and a preparation method and application thereof. Background Art
[0002] Cadmium (Cd) is one of the most toxic and widely distributed heavy metals known to date. It can cause many human diseases, such as the well-known Itai-itai disease and cancer (Tan HW, et al. Rev EnvironContam Toxicol, 2023). As early as 1993, cadmium was listed as a Class I carcinogen by the International Agency for Research on Cancer (IARC) (IARC, 1993). Eating cadmium-contaminated food, drinking cadmium-contaminated water, smoking, and occupational cadmium exposure are the most common ways of cadmium exposure (Fowler BA, et al. Toxicol Appl Pharmacol, 2009; Wang P, et al. Environ Pollut, 2019). The excretion of cadmium from the body is a very long process, and its biological half-life in the human body is as long as 10 to 40 years (Järup L, et al. Toxicol Appl Pharmacol, 2009). Therefore, when cadmium is absorbed by the human body, it is easy to accumulate in the body, causing long-term and serious damage to the digestive system, respiratory system, urinary and reproductive system, and circulatory system.
[0003] At present, there are antioxidants and chelation methods to treat cadmium poisoning. Cadmium, as a metal ion, has strong oxidizing properties. One way it harms the human body is by causing cellular oxidative stress. At this time, antioxidants can be used to treat cadmium poisoning. Antioxidants include natural or synthetic chemicals in nature, such as proteases and antioxidant compounds in organisms. Antioxidants mainly reduce damage to DNA, cell biomembranes, etc. by removing free radicals. Cadmium can cause cell damage in a variety of ways, and causing oxidative stress is only one of them, so antioxidants have little effect on the treatment of cadmium poisoning. The principle of chelation is that chelators can interact with metal ions to form complex ring structures and then be excreted from the body (Kim JJ, et al. J Trace Elem Med Biol, 2019). Related studies have shown that some chemical chelators such as ethylenediaminetetraacetic acid and 2,3-dimercaptopropanol can increase the excretion of cadmium in urine by intraperitoneal injection (Aposhian, HV, Toxicology, 1995). However, chelating agents can also bring about significant side effects when treating cadmium poisoning. Although the chelating agents currently used in animal experiments can increase the excretion of urinary cadmium, the dosage of the chelating agents used is generally very high, which can easily cause organ damage. In addition, in addition to interacting with cadmium, chelating agents can also chelate trace element ions in the body, thereby causing trace element deficiency (Domingo JL, et al. Reprod Toxicol, 1998). Therefore, the development of anti-cadmium toxicity drugs with better efficacy and fewer side effects has urgent clinical research and market needs. Summary of the invention
[0004] The purpose of the present invention is to disclose a polypeptide fragment and a preparation method and application thereof, so as to solve one or more technical problems existing in the prior art and provide at least one beneficial option or create conditions.
[0005] The first aspect of the present invention is to provide a polypeptide fragment capable of binding to cadmium ions.
[0006] The second aspect of the present invention is to provide a method for preparing the polypeptide fragment.
[0007] The third aspect of the present invention is to provide application directions of the polypeptide fragment.
[0008] The first aspect of the present invention is to provide a polypeptide fragment. The polypeptide fragment contains an amino acid sequence as shown in SEQ ID No: 1. The amino acid sequence shown in SEQ ID No: 1 is derived from 9 amino acid residues at the N-terminus of nucleolar phosphatidylcholine (NPM1). NPM1 is involved in various cellular processes, including ribosome maturation, centrosome duplication, maintenance of genome stability, cell cycle control and apoptosis, etc. It is a key role in cells, which can promote ribosome nuclear export, associate with nucleolar ribonucleoprotein structure, and interact with single-stranded nucleic acids. However, there is no record in the prior art that NPM1 has resistance to cadmium toxicity.
[0009] Experiments have shown that the cell model exposed to cadmium can significantly improve the survival rate after being treated with the polypeptide fragment; the animal model exposed to cadmium also improves the symptoms of liver damage and weight loss after being treated with the polypeptide fragment.
[0010] The second aspect of the present invention is to provide a method for preparing a polypeptide fragment. The preparation method comprises the following steps: (1) obtaining a DNA fragment as shown in SEQ ID No: 2, adding a sticky end and connecting it with a linearized expression plasmid, transferring it into Escherichia coli DH5α for expansion culture, breaking the bacterial cells and extracting to obtain a recombinant plasmid; (2) transferring the recombinant plasmid into Escherichia coli BL21 (DE3) and inducing expression; (3) after the induction of expression, collecting the bacterial cells by centrifugation, resuspending them in PBS buffer, ultrasonicating them on ice until the bacterial liquid becomes clear, and then centrifuging to collect the supernatant; (4) adding GSH agarose gel beads to the collected supernatant and incubating for 6 to 8 hours, discarding the supernatant after centrifugation, and washing with PBS buffer; (5) intercepting the polypeptide bound to the GSH agarose gel beads and removing the GST tag to obtain a semi-finished product solution; (6) dialyzing, precipitating, washing and drying the semi-finished product solution to obtain the polypeptide fragment.
[0011] In some application embodiments of the second aspect of the present invention, the expression plasmid is pGEX-5X-1, and the culture medium for expansion contains ampicillin (AMP).
[0012] In some application embodiments of the second aspect of the present invention, the induced expression is induced by adding isopropyl-β-d-thiogalactoside (IPTG) solution, the final concentration of the IPTG solution is 0.5 μmol / L, and the induction time is 4 hours.
[0013] The third aspect of the present invention is to provide the application of the polypeptide fragment. The application is to improve the cadmium resistance of animals by directly applying the polypeptide fragment; and to provide the application of the polypeptide fragment in the preparation of products with anti-cadmium toxicity activity; and to provide the application of the polypeptide fragment in the preparation of products for treating and / or preventing cadmium poisoning.
[0014] In some application embodiments of the third aspect of the present invention, the dosage form of the product is one of powder, paste, gel, drops, suppositories, tablets, granules, capsules, sprays, tablets or pills.
[0015] In some application embodiments of the third aspect of the present invention, the product further contains a physiologically acceptable carrier or excipient.
[0016] Compared with the existing detection technology, the present invention has the following advantages:
[0017] In the cell model experiment of cadmium exposure, the HeLa and H1299 cells were first pretreated with the polypeptide fragment, which can significantly improve the survival rate of the cell model in the subsequent cadmium exposure experiment. In the BALB / c mouse model experiment of cadmium exposure, the polypeptide fragment was injected into the tail vein, which can significantly reduce the levels of AST and ALT in the serum of mice and the degree of immune cell infiltration in the liver of mice, and improve the weight loss of mice caused by cadmium. The experimental results prove that the polypeptide fragment has pharmacological activity in treating cell and body damage caused by cadmium exposure, and has the prospect of being developed as a drug for the treatment of related diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 1 is a graph showing the results of Coomassie Brilliant Blue (CBB) staining and immunoblotting (IB) detection in Example 1;
[0019] Figure 2 is an analysis diagram of the Cd-IMAC and immunoblotting detection results in Example 1;
[0020] Figure 3 The polypeptide fragment in Example 3 is 2+ Histogram of ICP-MS test results of binding capacity;
[0021] Figure 4 is a bar graph showing the effect of the polypeptide fragments described in Example 4 on the survival rate of cells exposed to CdCl2;
[0022] Figure 5 is a bar graph of the results of mammalian cell toxicity test of the polypeptide fragment described in Example 5;
[0023] Figure 6 is a bar graph showing the effect of the polypeptide fragments described in Example 6 on the body weight of BALB / c mice exposed to cadmium;
[0024] Figure 7 is a bar graph showing the effects of the polypeptide fragments described in Example 6 on serum AST and ALT levels in BALB / c mice exposed to cadmium;
[0025] Figure 8 This is the H&E staining image of the liver of BALB / c mice exposed to cadmium by the polypeptide fragment described in Example 6;
[0026] Fig. 9 This is a bar graph showing the statistical results of the effects of the polypeptide fragments described in Example 6 on the infiltration of immune cells in the liver of BALB / c mice exposed to cadmium. DETAILED DESCRIPTION
[0027] The following examples further illustrate the content of the present invention, but should not be construed as limiting the present invention. Without departing from the spirit and essence of the present invention, modifications and substitutions made to the methods, steps or conditions of the present invention all belong to the scope of the present invention.
[0028] Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
[0029] The molecular biology experimental methods not specifically described in the following examples are all carried out with reference to the Molecular Cloning Experiment Guide (3rd edition) or in accordance with the kits and product instructions; the biological materials of the kits, unless otherwise specified, can be obtained from commercial channels.
[0030] The examples respectively record "M / D-rich", "Biotin-M / D-rich" and "Biotin-M to V", wherein "M / D-rich" is a polypeptide fragment with an amino acid sequence as shown in SEQ ID No: 1, "Biotin-M / D-rich" is "M / D-rich" with biotin connected to the N-terminus, and "Biotin-M to V" is a polypeptide fragment with Met mutated to Val in a simulated manner based on "Biotin-M / D-rich". The above polypeptides are synthesized by Beijing Baipeptide Biotechnology Co., Ltd.
[0031] The drugs and animals involved in the examples include: Streptavidin Mag Sepharose beads, Glutathione Sepharose TM 4B beads and Ni-NTA Sepharose TM 6 Fast Flow beads were purchased from GE Healthcare; SPF-grade BALB / c mice were purchased from Beijing Weitonglihua Experimental Animal Co., Ltd.
[0032] Example 1: Effect of polypeptide fragment length on Cd 2+ Binding capacity affects detection
[0033] Preliminary experiments have found that NPM1 has a certain amount of Cd 2+ To verify the origin of its binding ability, peptide chains of different regions and lengths were cut from NPM1 for Cd2+ Binding ability test.
[0034] (1) Construction of recombinant plasmids pGEX-5X-1-GST-NPM1, pGEX-5X-1-GST-NPM1-ΔM / D-rich, pGEX-5X-1-GST-NPM1-ΔN, and pGEX-5X-1-GST-NPM1-ΔC.
[0035] The primers for amplifying NPM1 and its truncations were designed based on the multiple cloning site of pGEX-5X-1 and the DNA sequence of NPM1 as shown in Table 1.
[0036] Among them, the amplification procedure of GST-NPM1 uses forward primer 1 and reverse primer 1; the amplification procedure of GST-ΔM / D-rich uses forward primer 2 and reverse primer 1; the amplification procedure of GST-NPM1-ΔN uses forward primer 3 and reverse primer 1; the amplification procedure of GST-NPM1-ΔC uses forward primer 1 and reverse primer 2.
[0037] The target fragment was obtained by PCR amplification using the cDNA of BEAS-2B cells as a template. The PCR reaction conditions were: 95℃, 3 minutes; 95℃, 30 seconds, 58℃, 40 seconds, 72℃, 90 seconds, 25 cycles; 72℃, 5 minutes. The target fragment was double-digested with BamH I (TaKaRa) and Xho I (TaKaRa) and then recovered by gel. It was ligated into the pGEX-5X-1 plasmid double-digested with BamH I and Xho I using T4 DNA Ligase (TaKaRa). The ligation reaction conditions were: 22℃, 3 hours. The ligation product was transformed into Escherichia coli DH5α, and Luria-Bertani (LB) plates containing 100 μg / mL AMP were used and cultured in a 37℃ incubator overnight; a single colony was picked and inoculated into 3 mL of LB liquid medium containing 100 μg / mL AMP, and cultured at 37℃, 220 rpm constant temperature shaker for 14 hours, and the plasmid was extracted and sequenced.
[0038] (2) Transform the recombinant plasmid into Escherichia coli BL21 (DE3) and induce expression.
[0039] Transform E. coli BL21 (DE3) with the correctly sequenced plasmid, spread the transformed BL21 on an LB plate containing 100 μg / mL AMP, and culture it in a 37°C incubator overnight. In the clean bench, pick a single clone with a sterile pipette tip and inoculate it into 3 mL LB AMP+ liquid culture medium. Culture it in a constant temperature shaking incubator at 37°C and 220 rpm for 12-14 hours. Take 100 μL of the bacterial solution and transfer it to 100 mL LB AMP+ liquid culture medium, and culture it in a constant temperature shaking incubator at 37°C and 220 rpm for expansion. When the bacterial solution OD 600 =0.6~0.8, add an appropriate amount of 0.1 mM IPTG solution (final concentration of 0.5 μmol / L) to induce target protein expression, and the induction time is 4 hours. After induction, centrifuge at 4°C, 5000×g for 10 minutes to collect the bacteria. After centrifugation, discard the supernatant, resuspend the bacteria with 6 mL of pre-cooled PBS solution, and sonicate on ice for more than 20 minutes, with each sonication for 15 seconds and stop for 15 seconds, until the bacterial solution becomes clear. Centrifuge at 12000 rpm, 4°C for 30 minutes, collect the supernatant and transfer to a 15 mL centrifuge tube.
[0040] (3) Purification of induced expressed GST-NPM1 and its truncated forms.
[0041] 1) Preparation of Glutathione Sepharose TM 4B beads (GSH agarose beads). Take 260 μL of 80% cross-linked agarose beads, wash them three times with ultrapure water, and centrifuge them at 4°C, 500×g for 5 minutes.
[0042] 2) Add GSH agarose beads to the protein solution to be purified, mix well, and then place on a vertical mixer at 4°C, 9 rpm, and incubate for 6 to 8 hours.
[0043] 3) After incubation, centrifuge at 500×g for 5 minutes at 4°C and discard the supernatant.
[0044] 4) Wash the GSH agarose beads with PBS buffer to remove residual or non-specifically bound proteins (use 6 mL PBS buffer each time, shake up and down vigorously, and wash 8 times in total).
[0045] 5) After washing, centrifuge at 4°C, 500×g for 5 minutes and discard the supernatant.
[0046] (4) Removal of the GST tag of GST-NPM1 and its truncated forms.
[0047] 1) Add 100 μL of digestion buffer containing 1 μg of FactorXa enzyme to the cross-linked agarose beads containing GST-NPM1 and its truncations, mix well, and incubate at room temperature for 1.5 hours, mixing every 20 minutes.
[0048] 2) After incubation, centrifuge at 4°C, 500×g for 5 minutes and carefully transfer the supernatant to a new tube.
[0049] 3) Add 100 μL Xarrest to the tube TM Agarose, mix well and incubate at room temperature for 0.5 hours, mixing every 20 minutes to remove Factor Xa enzyme.
[0050] 4) After incubation, centrifuge at 4°C, 500×g for 5 minutes and carefully transfer the supernatant to a new tube.
[0051] 5) Take a portion of the protein solution for verification by SDS-PAGE and Coomassie Brilliant Blue staining, and store the rest at -80°C.
[0052] The preparation results are as follows Figure 1 As shown, the expression product was detected by Coomassie brilliant blue staining and immunoblotting. After the purified fusion protein was incubated with Factor Xa enzyme, the GST tag of the prokaryotic expressed fusion protein was successfully removed. Since the pGEX-5X-1 plasmid and BamH I restriction site were used in the preparation of NPM1 and its truncated form, the nucleotide fragment of 5'-GGGATCCTT-3' was added to the 5' end of the start codon sequence of the target fragment, so the N-terminus of the target fragments (NPM1, NPM1-ΔN, NPM1-ΔC and NPM1-ΔM / D-rich) finally obtained all retained a residual fragment (GIL) composed of glycine (Gly), isoleucine (Ile) and leucine (Leu). The amino acid sequence of the actually prepared NPM1 is shown in SEQ ID No:8, the amino acid sequence of NPM1-ΔN is shown in SEQ ID No:9, the amino acid sequence of NPM1-ΔC is shown in SEQ ID No:10, and the amino acid sequence of NPM1-ΔM / D-rich is shown in SEQ ID No:11.
[0053] (5) Immobilized metal ion affinity chromatography (IMAC).
[0054] 1) Preparation of Cd-NTA sepharose beads:
[0055] 1-1) Pipette 120 μL of 80% Ni-NTA Sepharose TM6 Fast Flow beads into a 1.5 mL centrifuge tube, add 1 mL of ultrapure water to the centrifuge tube to wash the Ni-NTA agarose gel beads, centrifuge at 500 × g for 2 minutes, and discard the supernatant.
[0056] 1-2) Add 1 mL of elution buffer (20 mmol / L phosphate buffer, 0.5 mol / L NaCl, 50 mmol / L ETA, pH 7.4) and incubate at 4°C on a vertical mixer at 9 rpm for 10 minutes to chelate the Ni on the Ni-NTA agarose gel beads. 2+ After incubation, the cells were allowed to stand for 2 minutes, then centrifuged at 500 × g for 2 minutes and the supernatant was discarded.
[0057] 1-3) Repeat steps 1-2) once.
[0058] 1-4) After washing the NTA agarose beads with 1 mL of ultrapure water, let it stand for 2 minutes, then centrifuge at 500 × g for 2 minutes and discard the supernatant.
[0059] 1-5) Repeat steps 1-4) twice.
[0060] 1-6) Add 500 μL of 50 mmol / L CdCl2 to the centrifuge tube to make Cd 2+ Combined with NTA agarose gel beads, 500 μL of ultrapure water was added to the control group, and then the NTA agarose gel beads were placed on a vertical mixer at 4°C and incubated at 9 rpm for 8 hours.
[0061] 1-7) After incubation, centrifuge at 4°C, 500×g for 2 minutes and discard the supernatant. 2+ After being cleaned with ultrapure water, Cd-NTA agarose gel beads and control NTA agarose gel beads were prepared.
[0062] 2) Incubation of prokaryotically expressed NPM1 and its truncations with Cd-NTA agarose gel beads:
[0063] 2-1) Add 1 mL of Binding Buffer to the Cd-NTA agarose gel beads and the control group, and incubate at 9 rpm on a vertical mixer for 30 minutes (to pre-equilibrate the Cd-NTA agarose gel beads). After pre-equilibration, let stand for 2 minutes, centrifuge at 4°C, 500×g for 2 minutes, and discard the supernatant.
[0064] 2-2) Add the prokaryotic expressed NPM1 and its truncations obtained in step 3 to each group of agarose gel beads, mix well, and then incubate at 4°C on a vertical mixer at 9 rpm for 8 hours.
[0065] 2-3) After incubation, centrifuge at 500×g for 5 minutes at 4°C, then transfer the agarose beads to a 15 mL centrifuge tube, add 10 mL binding buffer, and wash away the remaining unbound or non-specifically bound proteins. Centrifuge at 500×g for 2 minutes and discard the supernatant.
[0066] 2-4) Repeat steps 2-3) 8 to 10 times to wash away proteins non-specifically bound to the agarose beads.
[0067] 2-5) After washing the agarose beads, transfer them to a new 1.5 mL centrifuge tube, add 100 μL 2×SDS protein loading buffer, heat in a 95°C metal bath for 10 minutes, then centrifuge at 8000×g for 5 minutes, and transfer the supernatant to a new 1.5 mL centrifuge tube.
[0068] 2-6) Take some samples and detect them by immunoblotting using NPM1 antibody (Santa Cruz).
[0069] The results of Cd-IMAC and immunoblotting were as follows Figure 2 As shown, a specific band was detected in the Cd-NTA agarose bead group in the NPM1 group, but no band was detected in the NTA agarose bead control group, indicating that NPM1 can bind to cadmium. Similarly, it was found that NPM1-ΔC containing the M / D-rich polypeptide sequence can also bind to cadmium, while NPM1-ΔN and NPM1-ΔM / D-rich without the M / D-rich polypeptide sequence cannot bind to cadmium.
[0070] It was also verified that the residual fragment (GIL) did not have the ability to bind cadmium, so it was confirmed that the ability of NPM1 and NPM1-ΔC to bind cadmium was brought by the M / D-rich peptide in the fragment.
[0071] Example 2: Preparation of polypeptide fragments
[0072] (1) Construction of recombinant plasmid pGEX-5X-1-GST-M / D-rich.
[0073] The DNA fragment encoding the M / D-rich polypeptide synthesized by Guangzhou Aiji Biotechnology Co., Ltd.: 5'-ATGGAAGATTCGATGGACATGGACATG-3' (SEQ ID No: 2) was double-digested with BamH I (TaKaRa) and Xho I (TaKaRa), and then ligated into the pGEX-5X-1 plasmid double-digested with BamH I and Xho I using T4 DNA Ligase (TaKaRa). The ligation reaction conditions were: 22°C, 3 hours. The ligation product was transformed into Escherichia coli DH5α, and cultured overnight in a 37°C incubator using an LB plate containing 100 μg / mL AMP. A single colony was picked and inoculated into 3 mL of LB liquid culture medium containing 100 μg / mL AMP, and cultured at 37°C, 220 rpm constant temperature shaker for 14 hours, and the plasmid was extracted and sequenced.
[0074] (2) Transform the recombinant plasmid into Escherichia coli BL21 (DE3) and induce the expression of the fusion protein.
[0075] 1) Transform E. coli BL21 (DE3) with the plasmid sequenced correctly in step 1, spread the transformed BL21 on LB plates containing 100 μg / mL AMP, and culture in a 37°C incubator overnight.
[0076] 2) In the clean bench, use a sterile pipette to pick up a single clone and inoculate it into 3 mL LB AMP+ liquid medium. Incubate in a constant temperature shaking incubator at 37°C and 220 rpm for 12-14 hours.
[0077] 3) Take 100 μL of bacterial solution and transfer it to 100 mL of LB AMP+ liquid culture medium, and culture it in a constant temperature shaking incubator at 37°C and 220 rpm for expansion. 600 =0.6-0.8, add an appropriate amount of 0.1 mM IPTG solution (final concentration 0.5 μmol / L) to induce target protein expression, and the induction time is 4 hours.
[0078] 4) After induction, centrifuge at 4℃, 5000×g for 10 minutes to collect the cells. After centrifugation, discard the supernatant, resuspend the cells with 6 mL of pre-cooled PBS solution, and sonicate on ice for more than 20 minutes, sonicating for 15 seconds each time and stopping for 15 seconds until the bacterial solution becomes clear. Centrifuge at 12000 rpm, 4℃ for 30 minutes, collect the supernatant and transfer it to a 15 mL centrifuge tube.
[0079] (3) Purify the induced expressed GST-M / D-rich.
[0080] 1) Preparation of Glutathione Sepharose TM4B beads (GSH agarose beads). Take 260 μL of 80% cross-linked agarose beads, wash them three times with ultrapure water, and centrifuge them at 4°C, 500×g for 5 minutes.
[0081] 2) Add the cross-linked agarose beads to the protein solution to be purified, mix well, and then place on a vertical mixer at 4°C, 9 rpm, and incubate for 6 to 8 hours to obtain GST-M / D-rich agarose gel beads.
[0082] 3) After incubation, centrifuge at 500×g for 5 minutes at 4°C and discard the supernatant.
[0083] 4) Wash the beads with PBS buffer to remove any residual or non-specifically bound proteins (use 6 mL of PBS buffer each time, shake vigorously up and down, and wash 8 times in total).
[0084] 5) After washing, centrifuge at 4°C, 500×g for 5 minutes and discard the supernatant.
[0085] (4) Remove the GST tag of GST-M / D-rich.
[0086] 1) Add Factor Xa enzyme buffer to the agarose beads containing GST-M / D-rich obtained in step 3, mix well, and incubate at room temperature for 1.5 hours, mixing every 20 minutes.
[0087] 2) After incubation, centrifuge at 4°C, 500×g for 5 minutes and carefully transfer the supernatant to a new tube to avoid aspirating the beads.
[0088] 3) Add Xarrest to the tube TM Agarose, mix well and incubate at room temperature for 0.5 hours, mixing every 20 minutes to remove Factor Xa enzyme.
[0089] 4) After incubation, centrifuge at 4°C, 500×g for 5 minutes and carefully transfer the supernatant to a new tube.
[0090] (5) Concentration and desalting of M / D-rich peptides.
[0091] 1) Add the M / D-rich peptide in the new tube to the dialysis bag and dialyze it in 1×PBS (phosphate buffered saline) at 4°C for 8 hours. After the dialysis is completed, carefully remove all the solution in the dialysis bag, which is the desalted M / D-rich peptide solution.
[0092] 2) Add 4 times the volume of -20℃ precooled acetone to the above M / D-rich peptide solution, mix well and place at -20℃ for 8 hours to precipitate the M / D-rich peptide.
[0093] 3) After precipitation, centrifuge at 16,000 × g, 4°C for 15 minutes and discard the supernatant.
[0094] 4) Add 1 mL of -20℃ precooled acetone to the tube, invert 4 to 6 times, centrifuge at 16,000×g, 4℃ for 15 min, carefully remove the supernatant, and then centrifuge at 16,000×g, 4℃ for 1 min.
[0095] 5) Use a pipette to remove the residual acetone, and then air-dry in a fume hood for 5 minutes to obtain the M / D-rich peptide dry powder, which can be stored at -80°C.
[0096] Example 3: Cd of polypeptide fragments 2+ Binding capacity test
[0097] (1) Dissolve 0.15 μmol / L of Biotin-M / D-rich peptide and Biotin-M to V peptide in phosphate buffered saline (PBS, 20 mmol / L, pH 7.4), add 25 μL of Streptavidin Mag Sepharose to the dissolved Biotin-M / D-rich peptide solution, Biotin-M to V peptide solution and PBS control solution, seal with sealing film, and shake with a vertical mixer at 4°C at a speed of 12-18 rpm for 4 hours.
[0098] (2) After incubation, collect the magnetic beads with a magnetic separator, discard the supernatant and keep the precipitate. Add 1 mL of pre-cooled PBS solution to the tube, invert it for 30 seconds, then collect the magnetic beads with a magnetic separator, discard the supernatant and keep the precipitate. Repeat the washing for more than 5 times to obtain streptavidin affinity magnetic beads bound to the target polypeptide fragment.
[0099] (3) Add 1 mL of 10 mmol / L CdCl2 solution to the streptavidin affinity magnetic beads, seal with sealing film, and shake overnight at 4°C using a vertical mixer at a speed of 12-18 rpm. After incubation, collect the magnetic beads using a magnetic separator and aspirate the supernatant to avoid aspirating the precipitate. Add 1 mL of pre-cooled PBS solution to the tube, invert it back and forth for 30 seconds, then collect the magnetic beads using a magnetic separator, discard the supernatant and retain the precipitate. Repeat the washing for more than 5 times to complete the cleaning.
[0100] (4) Add 150 μL of 2% sodium dodecyl sulfate (SDS) to each tube, flick gently to mix, and place in a 95°C metal bath for 10 minutes. After cooling, centrifuge at 500×g for 3 minutes, and carefully transfer the supernatant to a new tube. Label the tubes as Biotin-M / D-rich group, Biotin-M to V group, and control group.
[0101] (5) Detection of Cd in each group using ICP-MS 2+ The content.
[0102] The results of ICP-MS testing are as follows Figure 3 As shown, Biotin-M / D-rich group Cd 2+ The content of p <0.05, with significant statistical difference), and the Cd 2+ The content of p <0.05, with significant statistical difference). The above results show that the polypeptide fragment has strong Cd 2+ The binding ability of the peptide fragment is increased by mutating the amino acid Met to Val. 2+ The binding capacity was significantly weakened.
[0103] Example 4: Survival analysis of peptide fragments on CdCl2 exposed cell model
[0104] (1) HeLa and H1299 cells were cultured at 1×10 4 / hole and 2.5×10 4 / well were inoculated into 96-well plates and cultured in a 37°C constant temperature incubator.
[0105] (2) After 24 hours, when the cell confluence was close to 80-90%, the cells were treated with CdCl2 and / or M / D-rich peptide for 24 hours. HeLa cells were divided into two groups: control group and M / D-rich group. The cells in the control group were treated with CdCl2 at concentrations of 0, 2, 4, and 8 μmol / L; the cells in the M / D-rich group were first pretreated with M / D-rich peptide at a concentration of 2.5 μmol / L for 1 hour, and after removing the excess peptide fragment solution, CdCl2 and 2.5 μmol / LM / D-rich peptide were applied, and the CdCl2 concentrations were 0, 2, 4, and 8 μmol / L, respectively. The grouping and operation procedures of H1299 cells were the same as those of HeLa cells, but the concentration of CdCl2 treated was changed to 0, 5, 20, and 40 μmol / L.
[0106] (3) The cell viability was determined using the naphthol blue black (NBB) method, as follows: 1) discard the culture medium in the 96-well plate, add 100 μL of 4% paraformaldehyde solution to each well, and incubate at room temperature for 8 min; 2) discard the paraformaldehyde, add 100 μL of 0.05% NBB solution to each well, and incubate at room temperature for 25 min; 3) discard the NBB, add 100 μL of double distilled water to each well to wash away the residual NBB solution, and remove all the double distilled water after washing three times; 4) add 100 μL of 0.5 mmol / L NaOH solution to each well, shake gently to mix, and measure the absorbance of the solution at 595 nm.
[0107] The experimental results are as follows Figure 4 As shown, Figure 4 (A) is a bar graph of HeLa cell survival rate. Figure 4 (B) shows the effect on the viability of H1299 cells. * p <0.05;** p <0.01. After exposure to CdCl2, the survival rates of HeLa and H1299 cells were significantly reduced; after pre-administration of the polypeptide fragment, the survival rates of HeLa and H1299 cells were significantly improved. The results show that the polypeptide fragment can prevent CdCl2 from damaging HeLa and H1299 cells and effectively improve the survival rate of CdCl2-exposed cells.
[0108] Example 5: Toxicity detection of polypeptide fragments on mammalian HeLa, H1299, H460 and BEAS-2B cells
[0109] HeLa, H1299, H460 and BEAS-2B cells were cultured at 1×10 4 / hole, 2.5×10 4 / hole, 0.8×10 4 / hole and 2×10 4 / well were inoculated into 96-well plates and cultured in a constant temperature incubator at 37°C. After 24 hours, when the cell confluence was close to 80-90%, the cells were treated with 0, 2.5, 10 and 25 μmol / L of M / D-rich polypeptide, respectively, and the cell survival rate was detected after 24 hours. The specific treatment steps are shown in Example 4.
[0110] The results are as follows Figure 5 As shown, Figure 5 (A) is a bar graph of HeLa cell survival rate; Figure 5 (B) is a bar graph of H1299 cell survival rate; Figure 5 (C) is a bar graph of H460 cell survival rate; Figure 5 (D) is a bar graph of BEAS-2B cell survival rate. Figure 5The results showed that the M / D-rich polypeptide had little toxicity to cells. After the cells were treated with 2.5, 10, and 25 μmol / L of the M / D-rich polypeptide, the survival rates were all above 95%, indicating that the polypeptide fragment had good safety.
[0111] Example 6: Experiment on the effect of polypeptide fragments on BALB / c mouse model caused by CdCl2 exposure
[0112] (1) SPF BALB / c mice aged 8 weeks and weighing 20-22 g were selected and placed in an SPF animal room with a temperature of 23°C and a 12 h / 12 h circadian rhythm. After 7 days of free access to food and water, they were randomly divided into groups.
[0113] (2) A total of 4 groups, 3 mice in each group, were solvent control group, M / D-rich peptide treatment group, CdCl2 treatment group and M / D-rich peptide treatment group. The mice in the solvent control group were injected with 100 μL of PBS solution through the tail vein every day, and then 100 μL of normal saline was injected intraperitoneally 1 hour later. The mice in the M / D-rich peptide treatment group were injected with 100 μL of M / D-rich peptide solution at a concentration of 30 mg / (kg•bw) through the tail vein every day, and then 100 μL of normal saline was injected intraperitoneally 1 hour later. The mice in the CdCl2 treatment group were injected with 100 μL of PBS solution through the tail vein every day, and then 100 μL of CdCl2 solution at a concentration of 2 mg / (kg•bw) was injected intraperitoneally 1 hour later. The mice in the M / D-rich peptide treatment group were injected with 100 μL of M / D-rich peptide solution at a concentration of 30 mg / (kg•bw) through the tail vein every day, and 1 hour later, 100 μL of CdCl2 solution at a concentration of 2 mg / (kg•bw) was injected intraperitoneally. The weight of the mice was recorded every day.
[0114] (3) On the 14th day, the mice were eyeballed and blood was collected. The mice were killed and their livers were collected.
[0115] The collected mouse blood samples were left at room temperature for 1 hour, then centrifuged at 4°C and 2000 rpm for 15 minutes, and the upper serum was transferred to a new tube. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected using the Abbott ARCHITECT C16000 automatic biochemical analyzer.
[0116] The collected mouse liver tissue was fixed with 4% paraformaldehyde at room temperature for 24 hours, dehydrated using a Leica automatic tissue dehydrator, and embedded in paraffin after dehydration. The paraffin-embedded tissue was then made into 3 μm thick slices and stained with hematoxylin-eosin (H&E) using a SAKURA Tissue-Tek DRS2000 instrument. The stained slices were scanned using a Pannoramic 250 digital slice scanner, and histological analysis was performed using Case viewer 2.3 software.
[0117] The weight test results are as follows Figure 6 As shown, CdCl2 exposure caused a significant decrease in the body weight of mice (compared with the solvent control group, p <0.05, with significant statistical difference). After the M / D-rich peptide was injected into the tail vein, the body weight of mice increased significantly (compared with the CdCl2 alone treatment group, the M / D-rich peptide treatment group p <0.05, with significant statistical difference), indicating that the polypeptide fragment can significantly reduce the toxic effect of CdCl2 on mice. The body weight of mice in the group treated with M / D-rich polypeptide alone did not change significantly, indicating that the polypeptide fragment had no obvious toxicity to mice.
[0118] like Figure 7 (A) and Figure 7 As shown in (B), CdCl2 exposure significantly increased the AST and ALT levels in mice (the CdCl2-treated group was compared with the solvent control group, p <0.05, with significant statistical difference), while after pre-administration of M / D-rich peptide, the body weight and serum AST and ALT levels of mice decreased significantly (compared with the CdCl2 alone treatment group, p <0.05, with significant statistical difference), indicating that the polypeptide fragment can significantly improve the liver dysfunction caused by CdCl2 in mice. At the same time, there was no significant change in the serum AST and ALT levels of mice after they were treated with M / D-rich polypeptide alone (there was no significant change in the M / D-rich polypeptide alone treatment group compared with the solvent control group), indicating that the polypeptide fragment had no significant effect on the liver function of mice.
[0119] H&E staining of mouse liver tissue Figure 8 The statistical immune cell infiltration data are shown in Fig. 9 As shown, CdCl2 exposure significantly increased the infiltration of immune cells in the liver tissue of mice (compared with the solvent control group, the CdCl2-treated group p<0.05, with significant statistical difference). After pre-administration of M / D-rich peptide, the infiltration of immune cells in the liver tissue of mice was significantly reduced (compared with the CdCl2 alone treatment group, the M / D-rich peptide treatment group p <0.05, with significant statistical difference), indicating that the polypeptide fragment can significantly improve the liver damage caused by CdCl2 to mice. At the same time, there was no significant change in the morphological structure of the liver tissue of mice in the M / D-rich polypeptide alone treatment group, and the immune cell infiltration remained at a low level, with no significant difference from the solvent control group, indicating that the polypeptide fragment had no obvious toxicity to the mouse liver. The above results show that the polypeptide fragment can significantly improve the weight loss and liver damage of mice caused by CdCl2 exposure.
[0120] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the present invention can be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the embodiments should be considered exemplary and non-restrictive in all respects, and the scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims be included in the present invention.
Claims
1. A polypeptide fragment, characterized in that: The amino acid sequence shown in SEQ ID No:
1.
2. A method for preparing a polypeptide fragment, characterized in that: Includes steps: (1) Obtaining a DNA fragment as shown in SEQ ID No: 2, adding sticky ends and connecting it with a linearized expression plasmid, transferring it into Escherichia coli DH5α for expansion and culture, breaking the cells and extracting to obtain a recombinant plasmid; (2) transforming the recombinant plasmid into Escherichia coli BL21 (DE3) and inducing expression; (3) After induction of expression, the cells were collected by centrifugation, resuspended in PBS buffer, and sonicated on ice until the bacterial solution became clear, and then centrifuged to collect the supernatant; (4) Add GSH agarose beads to the collected supernatant and incubate for 6-8 hours. After centrifugation, discard the supernatant and wash with PBS buffer; (5) intercepting the polypeptide bound to the GSH agarose beads and removing the GST tag to obtain a semi-finished product solution; (6) The semi-finished product solution is dialyzed, precipitated, washed and dried to obtain the polypeptide fragment.
3. The preparation method according to claim 2, characterized in that: The expression plasmid is pGEX-5X-1, and the culture medium for the expanded culture contains ampicillin.
4. The preparation method according to claim 2, characterized in that: The induced expression is induced by adding isopropyl-β-d-thiogalactoside solution, the final concentration of the isopropyl-β-d-thiogalactoside solution is 0.5 μmol / L, and the induction time is 4 hours.
5. Use of the polypeptide fragment according to claim 1 in the preparation of a drug having anti-cadmium toxicity activity.
6. Use of the polypeptide fragment according to claim 1 in the preparation of a drug for treating and / or preventing cadmium poisoning.
